Note: Ingredients listed on restricted chemical lists
EC/CAS
9005-65-6
Name of the chemical
polyethyleneglycol sorbitan monooleate
Concentration
0.01%
General Information
Version
05
Revision date
2023-12-22
Product name
HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]
1.2.1 Relevant identified uses
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18
Manufacturer Name
Dynavax Technologies Corporation
Icons in SDS
Company Information
company name
Dynavax Technologies Corporation
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H373
Hazard statements
Code
Statements
H373
May cause damage to organs through prolonged or repeated exposure
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Exempt from requirements – product regulated as medicinal product (human vaccine; PFS)
Health hazards
Specific Target Organ Toxicity (Repeated or Prolonged Exposure), (Appendix A, Hazard Communication Standard, 29 CFR 1910.1200 A.9). Not classified. May cause damage to the kidneys, liver, spleen and hematopoietic system with prolonged or repeated exposure through parenteral route (Hazard Code H373).
Precautionary statements
Normal precautions common to safe manufacturing practice should be followed in handling and storage. Handle in accordance with good industrial hygiene and safety practices. Store refrigerated at temperatures from 2°C to 8°C (Storage Code P411).
2.3 Other hazards
None
